WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing…
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered…
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that…
ORION CORPORATION PRESS RELEASE 9 APRIL 2025 at 13.30 EEST Orion publishes Interim Report for January–March 2025 and holds…
Barbara Weber, M.D., Elected to ITM Supervisory Board Headshot Barbara Weber, M.D. Garching / Munich, Germany, April 09, 2025 –…
Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy…
New CCO Joins as Cytosurge Engages in Key Scientific Events Across the USA and BeyondZURICH, Switzerland, April 09, 2025 (GLOBE…
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025New Clinical Data from Phase 2 Extension Period…
New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech…
Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria…